肿瘤基因检测指导下个体化化疗应用于晚期非小细胞肺癌的临床观察

目的通过检测晚期非小细胞肺癌患者的相关肿瘤基因选择个体化化疗方案并观察疗效。方法将60例晚期NSCLC患者分为基因组和对照组,选择不同的化疗方案全身化疗,并观察中位生存指标(MST)和无进展生存期(PFS)。结果基因组及对照组中位生存期分别为11.3月和9.1月,两者比较有统计学意义(P<0.05),基因组及对照组无进展生存期分别为7.2月和5.3月,(P<0.05)。结论肿瘤基因检测指导下的个体化化疗能延长晚期NSCLC的生存周期。

Clinical observation of individualized chemotherapy on patients with advanced NSCLC under the guidance of cancer genes testing

Objective To select the individualized chemotherapy program and to observe therapeutic effect according to the detec- tion of related cancer genes of patients with advanced non small cell lung cancer. Methods 60 patients with advanced NSCLC were divid- ed into the gene group and the control group, and different chemotherapy programs were chosen. Median survival time （MST） and pro- gression-free survival （PFS） were observed. Results The average survival time （MST） of the gene group and the control group was 11.3 months and 9. 1 months respectively, with statistical significance （ P 〈 0. 05 ）. The time of progression-free survival （PFS） was 7.2 months and 5.3 months respectively in the gene group and the control group with significant difference （ P 〈 0. 05 ）. Conclusion The in- dividualized chemotherapy under the guidance of cancer genes testing can prolong the life cycle of patients with advanced NSCLC.